Richard Emmitt Sells 600,000 ev3 Shares

Richard Emmitt, a general partner at The Vertical Group and member of ev3 board of directors, sold $8.8 million worth of ev3 stock. The transaction was filed with SEC on Tuesday January 19th 2010, same day that J.P. Morgan upgraded the stock from Neutral to Overweight with a price target increase from $15 to $19.

Read more...

Richard Emmitt Sells 600,000 ev3 Shares

Richard Emmitt, a general partner at The Vertical Group and member of ev3 board of directors, sold $8.8 million worth of ev3 stock. The transaction was filed with SEC on Tuesday January 19th 2010, same day that J.P. Morgan upgraded the stock from Neutral to Overweight with a price target increase from $15 to $19.

Read more...

Palmisano: Neuro Intervention Market is $1 Billion

Robert Palmisano Estimates $950 Mil Neurovascular Intervention Market for the year 2010.

Announcement was made at JPMorgan Healthcare Conference later today (January 12th 2009).

Read more...

Palmisano: Neuro Intervention Market is $1 Billion

Robert Palmisano Estimates $950 Mil Neurovascular Intervention Market for the year 2010.

Announcement was made at JPMorgan Healthcare Conference later today (January 12th 2009).

Read more...

Palmisano: Aneurysm Flow Diversion $350 Million

Rober Palmisano Asserts earlier estimates of $350 million for Cerebral Aneurysm Flow Diversion Device Market by 2013.

Announcement was made at JPMorgan Healthcare Conference later today (January 12th 2009).

Read more...

Palmisano: Aneurysm Flow Diversion $350 Million

Rober Palmisano Asserts earlier estimates of $350 million for Cerebral Aneurysm Flow Diversion Device Market by 2013.

Announcement was made at JPMorgan Healthcare Conference later today (January 12th 2009).

Read more...

Chestnut Medical Technologies

Chestnut Medical Technologies was founded to pioneer new minimally invasive therapies for Interventional Neuroradiology. Chestnut's mission is to develop technologies that are easier to use while improving outcomes and reducing complications in the treatment of neurovascular disease.

Chestnut's first product is the Alligator Retrieval Device (ARD), an intracranial coil/stent foreign body retrieval system, the Alligator Retrieval Device, was cleared by the FDA in March 2005.

Chestnut Medical Technologies has also developed the Pipeline NED, a braided bimetallic stent for exclusion of cerebral aneurysms through flow disruption.

The Pipeline NED received European CE Mark approval in 2009 as a stand alone device for excluding cerebral aneurysms from circulation and Chestnut Medical Technologies was acquired by ev3 in June 2009 for a total provision of $150 million in cash, shares and milestone provisions.

Read more...

Chestnut Medical Technologies

Chestnut Medical Technologies was founded to pioneer new minimally invasive therapies for Interventional Neuroradiology. Chestnut's mission is to develop technologies that are easier to use while improving outcomes and reducing complications in the treatment of neurovascular disease.

Chestnut's first product is the Alligator Retrieval Device (ARD), an intracranial coil/stent foreign body retrieval system, the Alligator Retrieval Device, was cleared by the FDA in March 2005.

Chestnut Medical Technologies has also developed the Pipeline NED, a braided bimetallic stent for exclusion of cerebral aneurysms through flow disruption.

The Pipeline NED received European CE Mark approval in 2009 as a stand alone device for excluding cerebral aneurysms from circulation and Chestnut Medical Technologies was acquired by ev3 in June 2009 for a total provision of $150 million in cash, shares and milestone provisions.

Read more...

ev3 Neurovascular Intervention Business Unit

EV3 is a global medical device company focused on catheter-based technologies for the endovascular treatment of vascular diseases and disorders. EV3 is organized into two business segments, cardio peripheral and neurovascular.

During 2009 the company generated total revenue of $430 million of which $165 million, or 38% of total were generated from its neurovascular intervention strategic business unit.

EV3 neurovascular product range include Embolic Coils, Liquid Embolics, Neuro Stents, Microcatheters, Occlusion Balloon Systems and Guidewires.

In the Embolic Coils category the company products include the NXT line of detachable coils which was introduced in the United States and Europe in 2004, the Nexus line of coils which was introduced in the United States and Europe in September 2005 and the Axium line of  detachable coils which was launched globally in the 4th quarter of 2007.

In the Liquid Embolics category the company products include the Onyx Liquid Embolic System.   Onyx is a proprietary biocompatible copolymer which is delivered, in liquid form, through microcatheters to blood vessels in the brain, where it fills a vascular defect and transforms into a solid polymer cast. Onyx offers a unique form, fill and seal approach to the interventional treatment of aneurysms and AVMs associated with hemorrhagic stroke.

In the neuro-stent segment EV3 we received a CE mark for the neurovascular use of its new stent platform, the Solitaire, in December 2007. The company initiated limited commercialization of the Solitaire platform, a self-expanding Nitinol stent, in Europe for use in bridging the neck of aneurysms to facilitate more secure coil placement, with thrombo-embolic disease to immediately restore blood flow and assist in the removal of clot burden and with intracranial stenotic disease where vessels within the brain become narrowed.

The Solitaire is fully retrievable and detachable, allowing for more precise placement and if required, replacement of the stent is possible. The company estimate that it will receive an HDE (humanitarian device exemption) from the FDA for the same indication in 2009.

In June 2009 ev3 announced the acquisition of 100% equity interest in Chestnut Medical Technologies, the developer of the Pipeline Embolization Device (PED), for $26 million in cash and approximately 5 million shares of common stock, 65% of total upfront consideration of $75 million with additional milestone-based contingent payment of up to $75 million.

Pipeline Embolization Device (PED), a braided bimetallic stent for exclusion of cerebral aneurysms through flow disruption, received CE Mark approval in June 2008 and is currently undergoing clinical trials in the US for an FDA filling.

Chestnut Medical has also an intracranial coil/stent foreign body retrieval system, the Alligator Retrieval Device, which was cleared by the FDA in March 2005.

ev3 has a dedicated neurovascular sales force of over seventy representatives worldwide with  two-third of this sales forces deployed in Europe. The company is forecasting a market of $350 million by 2013 for PED device and is predicting a possible US launch as early as 2011.

Read more...

ev3 Neurovascular Intervention Business Unit

EV3 is a global medical device company focused on catheter-based technologies for the endovascular treatment of vascular diseases and disorders. EV3 is organized into two business segments, cardio peripheral and neurovascular.

During 2009 the company generated total revenue of $430 million of which $165 million, or 38% of total were generated from its neurovascular intervention strategic business unit.

EV3 neurovascular product range include Embolic Coils, Liquid Embolics, Neuro Stents, Microcatheters, Occlusion Balloon Systems and Guidewires.

In the Embolic Coils category the company products include the NXT line of detachable coils which was introduced in the United States and Europe in 2004, the Nexus line of coils which was introduced in the United States and Europe in September 2005 and the Axium line of  detachable coils which was launched globally in the 4th quarter of 2007.

In the Liquid Embolics category the company products include the Onyx Liquid Embolic System.   Onyx is a proprietary biocompatible copolymer which is delivered, in liquid form, through microcatheters to blood vessels in the brain, where it fills a vascular defect and transforms into a solid polymer cast. Onyx offers a unique form, fill and seal approach to the interventional treatment of aneurysms and AVMs associated with hemorrhagic stroke.

In the neuro-stent segment EV3 we received a CE mark for the neurovascular use of its new stent platform, the Solitaire, in December 2007. The company initiated limited commercialization of the Solitaire platform, a self-expanding Nitinol stent, in Europe for use in bridging the neck of aneurysms to facilitate more secure coil placement, with thrombo-embolic disease to immediately restore blood flow and assist in the removal of clot burden and with intracranial stenotic disease where vessels within the brain become narrowed.

The Solitaire is fully retrievable and detachable, allowing for more precise placement and if required, replacement of the stent is possible. The company estimate that it will receive an HDE (humanitarian device exemption) from the FDA for the same indication in 2009.

In June 2009 ev3 announced the acquisition of 100% equity interest in Chestnut Medical Technologies, the developer of the Pipeline Embolization Device (PED), for $26 million in cash and approximately 5 million shares of common stock, 65% of total upfront consideration of $75 million with additional milestone-based contingent payment of up to $75 million.

Pipeline Embolization Device (PED), a braided bimetallic stent for exclusion of cerebral aneurysms through flow disruption, received CE Mark approval in June 2008 and is currently undergoing clinical trials in the US for an FDA filling.

Chestnut Medical has also an intracranial coil/stent foreign body retrieval system, the Alligator Retrieval Device, which was cleared by the FDA in March 2005.

ev3 has a dedicated neurovascular sales force of over seventy representatives worldwide with  two-third of this sales forces deployed in Europe. The company is forecasting a market of $350 million by 2013 for PED device and is predicting a possible US launch as early as 2011.

Read more...

ev3 Promotes Pascal Girin & David Mowry

ev3 promots Pascal Girin to the newly created position of executive vice president and chief operating officer, and David Mowry to senior vice president and president, worldwide neurovascular.

As chief operating officer, Girin would have global operating responsibility for ev3's peripheral vascular, neurovascular and international businesses. Girin has served as ev3's executive vice president and president, worldwide neurovascular and international since July 2008.

In the new role, Mowry would have global responsibility for ev3's neurovascular business. Mowry has served as ev3's senior vice president, strategy and corporate operations since July 2008.

Read more...

ev3 Promotes Pascal Girin & David Mowry

ev3 promots Pascal Girin to the newly created position of executive vice president and chief operating officer, and David Mowry to senior vice president and president, worldwide neurovascular.

As chief operating officer, Girin would have global operating responsibility for ev3's peripheral vascular, neurovascular and international businesses. Girin has served as ev3's executive vice president and president, worldwide neurovascular and international since July 2008.

In the new role, Mowry would have global responsibility for ev3's neurovascular business. Mowry has served as ev3's senior vice president, strategy and corporate operations since July 2008.

Read more...

ev3 Appoints Robert Palmisano as CEO

ev3  announced today, April 7th 2008, the appointment of Robert J. Palmisano as President, Chief Executive Officer and Director, effective immediately. Mr. Palmisano succeeds James  Corbett, who has resigned as Chairman, President and Chief Executive Officer.

Mr. Palmisano brings more than 20 years of experience in the pharmaceutical and medical device industries to ev3. He most recently served as President and Chief Executive Officer of IntraLase Corp., a company that designs, develops and manufactures ultra-fast femtosecond laser technology for use in ophthalmology, which was acquired by Advanced Medical Optics,  in April 2007.

Read more...

ev3 Appoints Robert Palmisano as CEO

ev3  announced today, April 7th 2008, the appointment of Robert J. Palmisano as President, Chief Executive Officer and Director, effective immediately. Mr. Palmisano succeeds James  Corbett, who has resigned as Chairman, President and Chief Executive Officer.

Mr. Palmisano brings more than 20 years of experience in the pharmaceutical and medical device industries to ev3. He most recently served as President and Chief Executive Officer of IntraLase Corp., a company that designs, develops and manufactures ultra-fast femtosecond laser technology for use in ophthalmology, which was acquired by Advanced Medical Optics,  in April 2007.

Read more...

AXIUM Detachable Coil System - ev3

ev3 AXIUM Detachable Coil System,optimizes coil delivery, deployment and detachment. According to ev3 the AXIUM offers quick and easy detachment, smooth effortless delivery and smooth movement through microcatheter.

The AXIUM also minimizes set-up time with simple sheath system and precise, conformable deployment.

Other traits ev3 mentions of the AXIUM include:

• Responsive Placement and Repositioning
• Progressive coil diameter optimizes packing sequence
• Unique large loop 3D design minimizes compartmentalization
• Loop to length ratio enhances biomechanical stability
• Soft floating detachment link minimizes catheter kick out
• Instant, Reliable Detachment
• No Cables, No Boxes, No Batteries
• Single-handed Operation
• Quick and Easy Set-up

ev3 - AXIUM Neurovascular Embolic Coil System

Read more...

AXIUM Detachable Coil System - ev3

ev3 AXIUM Detachable Coil System,optimizes coil delivery, deployment and detachment. According to ev3 the AXIUM offers quick and easy detachment, smooth effortless delivery and smooth movement through microcatheter.

The AXIUM also minimizes set-up time with simple sheath system and precise, conformable deployment.

Other traits ev3 mentions of the AXIUM include:

• Responsive Placement and Repositioning
• Progressive coil diameter optimizes packing sequence
• Unique large loop 3D design minimizes compartmentalization
• Loop to length ratio enhances biomechanical stability
• Soft floating detachment link minimizes catheter kick out
• Instant, Reliable Detachment
• No Cables, No Boxes, No Batteries
• Single-handed Operation
• Quick and Easy Set-up

ev3 - AXIUM Neurovascular Embolic Coil System

Read more...

ev3 Nexus Neurovascular Embolic Coils

ev3 Nexus Detachable Coils are a line of coils that are designed to deliver softness, conformability and durability. Its design allows it to be used as a framing and filling coil of complex, amorphic aneurysm as well as satisfying routine coiling needs.

Nexus Tetris 3-D CSR 10 is an innovative starting coil that builds a supportive basket into which additional coils can be deployed.

Nexus Helix SuperSoft CSR is an enhanced coil for the filling and finishing stage it allows for safe deployment and increased filling.

ev3 Nexus Neurovascular Embolic Coils

Read more...

ev3 Nexus Neurovascular Embolic Coils

ev3 Nexus Detachable Coils are a line of coils that are designed to deliver softness, conformability and durability. Its design allows it to be used as a framing and filling coil of complex, amorphic aneurysm as well as satisfying routine coiling needs.

Nexus Tetris 3-D CSR 10 is an innovative starting coil that builds a supportive basket into which additional coils can be deployed.

Nexus Helix SuperSoft CSR is an enhanced coil for the filling and finishing stage it allows for safe deployment and increased filling.

ev3 Nexus Neurovascular Embolic Coils

Read more...

ev3 NXT Neurovascular Embolic Coils

ev3 NXT Detachable Coils are a family of bare coil for endovascular coiling. They are stretch resistance with three geometrical designs to achieve a customized fit with the aneurysm.

The NXT Tetris Detachable Coils fit and frame the aneurysm while the Tension Safe Nitinol filament technology delivers shape memory.

ev3 NXT Neurovascular Embolic Coils

Read more...

ev3 NXT Neurovascular Embolic Coils

ev3 NXT Detachable Coils are a family of bare coil for endovascular coiling. They are stretch resistance with three geometrical designs to achieve a customized fit with the aneurysm.

The NXT Tetris Detachable Coils fit and frame the aneurysm while the Tension Safe Nitinol filament technology delivers shape memory.

ev3 NXT Neurovascular Embolic Coils

Read more...